COVID-19 from a pharmacological perspective
- PMID: 34419772
- PMCID: PMC8366043
- DOI: 10.1016/j.jbior.2021.100821
COVID-19 from a pharmacological perspective
Similar articles
-
SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies.J Evid Based Med. 2020 Nov;13(4):255-260. doi: 10.1111/jebm.12414. Epub 2020 Oct 14. J Evid Based Med. 2020. PMID: 33058394 Free PMC article. No abstract available.
-
SARS-CoV-2-induced lung pathology: AHR as a candidate therapeutic target.Cell Res. 2021 Jan;31(1):1-2. doi: 10.1038/s41422-020-00447-9. Cell Res. 2021. PMID: 33262451 Free PMC article. No abstract available.
-
Potential small-molecule drugs as available weapons to fight novel coronavirus (2019-nCoV): A review.Cell Biochem Funct. 2021 Jan;39(1):4-9. doi: 10.1002/cbf.3576. Epub 2020 Aug 17. Cell Biochem Funct. 2021. PMID: 32803762 Free PMC article. Review.
-
COVID-19 and the liver: an adverse outcome pathway perspective.Toxicology. 2021 May 15;455:152765. doi: 10.1016/j.tox.2021.152765. Epub 2021 Mar 23. Toxicology. 2021. PMID: 33771662 Free PMC article. Review.
-
Antiviral drugs proposed for COVID-19: action mechanism and pharmacological data.Eur Rev Med Pharmacol Sci. 2021 Jun;25(11):4163-4173. doi: 10.26355/eurrev_202106_26060. Eur Rev Med Pharmacol Sci. 2021. PMID: 34156698 Review.
References
-
- Fung T.S., Liu D.X. Human coronavirus: host-pathogen interaction. Annu. Rev. Microbiol. 2019;73:529–557. - PubMed
-
- Johns Hopkins C.S.S.E. COVID-19 map – Johns Hopkins coronavirus Resource Center [accessed 2021 July 27] 2021. www.coronavirus.jhu.edu Available at:
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources